Functional evaluation of patients with chronic pulmonary hypertension

Italian Heart Journal

Volumn 6, Issue 10, 2005, Pages 789-794

  Guazzi, Marco ^a   Opasich, Cristina ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

Author keywords

Cardiopulmonary exercise test; Pulmonary hypertension; Six minute walk test

Indexed keywords

EXERCISE TEST; EXERCISE TOLERANCE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW;

EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; QUALITY OF LIFE;

EID: 33644668782     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
2. Enright PL. The six-minute walk test. Respir Care 2003; 48: 783-5.
3. Opasich C, Pinna GD, Mazza A, et al. Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications. Am J Cardiol 1998; 81: 1497-500.
4. Enright PL, Sherrill DL. Reference equations for the sixminute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384-7.
5. Borg GA. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81.
6. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161 (Part 1): 487-92.
7. Sztrymf B, Francoual J, Sitbon O, et al. Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension. Rev Mal Respir 2004; 21: 909-15.
8. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-34.
9. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-7.
10. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764-70.
11. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension Chest 2004; 126: 1452-9.
12. Barst RJ, Langleben D, Frost A, et al, for the STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-7.
13. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997; 16: 313-9.
14. Stricker H, Domenighetti G, Popov W, et al, on behalf of the Swiss Group for Severe Pulmonary Hypertension. Severe pulmonary hypertension: data from the Swiss Registry. Swiss Med Wkly 2001; 131: 346-50.
15. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
16. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-9.
17. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-8.
18. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
19. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43 (Suppl): 48S-55S.
20. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the sixminute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647-52.
21. McLaughlin VV, Presberg KW, Doyle RL, et al, for the American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 2004; 126 (Suppl): 78S-92S.
22. Peacock A, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004; 23: 947-53.
23. Olschewski H, Simonneau G, Galie N, et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension N Engl J Med 2002; 347: 322-9.
24. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-82.
25. Simonneau G, Barst RJ, Galie N, et al, for the Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
26. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
27. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.
28. Kawut SM, Palevsky HI. Surrogate end points for pulmonary arterial hypertension. Am Heart J 2004; 148: 559-65.
29. Wasserman K, Hansen JE, Sue DY, et al. Principles of exercise testing and interpretation. Malvern, PA: Lea & Febiger, 1994.
30. Guazzi M. Exercise testing to monitor heart failure treatment. In: Wasserman K, ed. Cardiopulmonary exercise testing and cardiovascular health. Armonk, NY: Futura Publishing Company, 2002: 221-38.
31. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429-35.
32. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation 2002; 105: 54-60.
33. Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000; 101: 2388-92.
34. Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004; 109: 351-6.
35. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-24.
36. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl): 48S-55S.
37. American Thoracic Society, American College of Chest Physicians. ATS/ ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-77.
38. Rhodes J, Barst RJ, Garofano RP, Thoele DG, Gersony WM. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991; 18: 1738-44.
39. Barst RJ, McGoon M, Laughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2115-25.
40. Barst RJ, Langleben D, Frost A, et al. Sitaxsetan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-7.
41. Hansen JE, Sun XG, Yasunobu Y, et al. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest 2004; 126: 816-24.
42. Koike A, Yajima T, Adachi H, et al. Evaluation of exercise capacity using submaximal exercise at a constant work rate in patients with cardiovascular disease. Circulation 1995; 91: 1719-24.
43. Guazzi M, Agostoni PG. Monitoring gas exchange during a constant work rate exercise in patients with left ventricular dysfunction treated with carvedilol. Am J Cardiol 2000; 85: 660-4.
44. Yetman AT, Taylor AL, Doran A, Dunbar Ivy D. Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. Am J Cardiol 2005; 95: 697-9.